A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes

Melanie J. Davies; Steve Baín; G. Charpentier; Frank Flacke; Harmonie Goyeau; Michael Woloschak; Christoph Hasslacher; Giacomo Vespasiani; Steven V. Edelman

doi:10.1177/1932296818821706

January 15, 2019Journal of Diabetes Science and TechnologyOpen Access

A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes

View Full Paper

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

Device-supported self-titration had a good safety/efficacy profile, and was noninferior to routine titration and well accepted by diabetes specialists and patients.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davies et al. (2019) studied this question.

synapsesocial.com/papers/69d7d3fff39344339dd189b4 https://doi.org/10.1177/1932296818821706

View Full Paper

Ask AI

Bookmark

Share

A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes

Abstract

Ask about this paper

Discussion

Cite This Study

A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading